Sutureless transconjunctival 20 g pars plana vitrectomy

Article

Sutureless transconjunctival 20 g ppv is, according to this study, an ideal technique for all vitreoretinal surgeries.

Key Points

Minimally invasive techniques have been introduced across virtually the whole spectrum of surgery. In ophthalmology sutureless operating techniques in cataract surgery and recently in vitrectomy offer less postoperative inflammation, shorter intraoperative and recovery time. In this article is reported the evaluation, feasibility and safety of the Sutureless Transconjuctival 20 Gauge Vitrectomy (20 STV).

How the technique works

Subconjunctival antibiotics and corticosteroids are used at the end of the procedure. Few fluid filled eyes had minimal leakage of fluid. Eyes with air or gas fill are less likely to be hypotonous at the end of theoperation. Eyes that ended up with silicone oil had no leakage at all due to higher viscosity of the oil. The pressure of the eyes at the end of the operation was either normal or slightly low. In cases where hypotony was noticed additional air or fluid was injected through pars plana with a 27 gauge needle. Slight chemosis occurred in a few cases.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
© 2025 MJH Life Sciences

All rights reserved.